Jade Biosciences, Inc.: Venrock Healthcare Capital Partners III, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Venrock Healthcare Capital Partners III, L.P. amended its Schedule 13G filing for Jade Biosciences, Inc., disclosing a change in its beneficial ownership stake under SEC accession number 0001738048-26-000094. The filing, submitted to the U.S. Securities and Exchange Commission, updates the venture firm's previously reported position in the biotechnology company. Schedule 13G amendments are typically required when a passive investor's ownership crosses certain thresholds or when previously reported holdings change materially. The specific size and direction of the stake adjustment were not detailed in the filing headline, leaving investors to review the full document for exact share counts and percentages. The update matters because it signals a shift in a major institutional holder's position in Jade Biosciences, and market watchers will look to the amended filing for precise ownership figures and any indication of Venrock's future intentions.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Jade Biosciences, Inc., Venrock Healthcare Capital Partners III, L.P.